ActoFactor™ Recombinant Human Vascular endothelial cell growth factor 189

Specification
Recommended Products

Cat.No.

CSC-CTK0395

Description

VEGF-A is a polypeptide growth factor and a member of the platelet-derived growth factor family. It is a specific mitogen for vascular endothelial cells and a strong angiogenic factor in vivo. 5 different VEGF-A proteins are generated by diffential splicing: VEGF-121, VEGF-145, VEGF- 165, VEGF-189 and VEGF-206. The most abdundant form is VEGF-165. Whereas VEGF-121 and VEGF-165 are secreted proteins, VEGF-145, VEGF-189 and VEGF-206 are strongly cell- associated. The isoforms VEGF-145, VEGF-165 and VEGF-189 bind to heparin with high affinity. VEGF-165 is apparently a homo-dimer, but preparations of VEGF-165 show some heterogeneity on SDS gels, depending on the secretion of different glycosylation patterns. All dimeric forms have similar biological activities but their bio-availability is very different. There is good evidence that heterodimeric molecules between the different isoforms also exists and that different cells and tissues express different VEGF isoforms. The other members of this in-creasing growth factor family are VEGF-B, -C, -D and -E. Another member is the Placenta growth factor PlGF. Two high-affinity tyrosine kinase receptors for VEGF-165 have been identified, VEGFR-1 (FLT-1), and VEGFR-2 (KDR). Consistent with the endothelial cell-specific action of VEGF-165, expression of both receptor genes has been found predominantly but not exclusively on endothelial cells. Expression of VEGFR-1 was also found on human monocytes, neutrophils (PMNs), bovine brain pericytes and villous and extravillous tropho-blasts. In addition to its action as a mitogen it is a potent vasular permeability factor (VPF) in vivo. VEGF-165 is also a chemoattractant molecule for monocytes and endothelial cells. |Human Vascular Endothelial Growth Factor 189 produced in E. coli is a 21 kDa homodimeric protein of 189 amino acid residues and approximately 42 kDa.

Species

Human

Product Overview

Human VEGFA expressed in E.coli

Molecular Mass

42 kDa

Size

CAT# CSC-CTK0395-20 (20 μg); CAT# CSC-CTK0395-100 (100 μg)

Expression System

E.coli

Purity

Greater than 98% as determined by SDS-PAGE analysis.

Activity

The ED50 for stimulation of cell proliferation of human umbilical vein endothelial cells is typically in the range between 2-20 ng/ml.

Endotoxin Level

Less than 1 EU/μg.

Formulation

Lyophilized from a protein solution in 50 mM acetic acid with no additives.

Reconstitution

Please centrifuge product briefly before opening the vial. The lyophilized human VEGF should be reconstituted in sterile, ultrapure water to a concentration of 0.1 - 1.0 mg/ml. This solution can then be diluted into other aqueous buffers and stored at -20°C for future use.

Storage & Stability

The lyophilized powder, though stable at room temperature for up to 3 weeks, is best stored desiccated at -20°C. Reconstituted rHu VEGF should be stored long-term in undiluted working aliquots at –20°C. For long-term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid repeated freeze / thaw cycles.

Citation Guidance

If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

CSC-CTK0092

ActoFactor™ Recombinant Human Angiopoietin 1

INQUIRY

CSC-CTK0093

ActoFactor™ Recombinant Human Apolipoprotein A-I

INQUIRY

CSC-CTK0094

ActoFactor™ Recombinant Human Apolipoprotein E2

INQUIRY

CSC-CTK0095

ActoFactor™ Recombinant Human Apolipoprotein E3

INQUIRY